News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apricus Biosciences (APRI) Announces Corporate Update and Second Quarter 2014 Financial Results Conference Call



8/4/2014 3:44:05 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company's second quarter financial results will be released with the issuance of its Report on Form 10-Q on Monday, August 11, 2014. Company management will host a conference call on Tuesday, August 12, 2014, at 8:00 a.m. ET to discuss the financial results and other recent corporate highlights.

To participate by telephone, please dial 877-407-9210 (Domestic) or 201-689-8049 (International). The conference ID number is 13588208. The live and archived audio webcast can be accessed via the following link: http://www.investorcalendar.com/IC/CEPage.asp?ID=173060 or on the Company's website at www.apricusbio.com. A replay of the call will be available by dialing 877-660-6853 (Domestic) or 201-612-7415 (International). The archived webcast will remain available for three months following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company focused on the development and commercialization of novel therapeutics for men's and women's health. The Company's lead product, Vitaros™, for the treatment of erectile dysfunction, is approved in Europe and Canada and will be commercialized by Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The Company's second-generation Vitaros™ room temperature device is under development and is expected to enhance the product's commercial value. RayVa™, the Company's product candidate for the treatment of Raynaud's phenomenon, recently received FDA clearance to begin clinical studies. The Company intends to begin a Phase 2a trial with RayVa in the second half of 2014. Femprox™, the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. The Company is currently seeking a strategic partner for Femprox.

For further information on Apricus, visit http://www.apricusbio.com.

CONTACT: Steve Martin Apricus Biosciences Chief Financial Officer ir@apricusbio.com (858) 222-8041 Investors: Angeli Kolhatkar Burns McClellan Senior Vice President akolhatkar@burnsmc.com (212) 213-0006

Apricus logo

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES